公开(公告)号：BR112013023960B1

公开(公告)日：2020-12-01

申请号：BR112013023960

申请日：2012-01-16

Applicant: STICHTING VUMC ,  VER VOOR CHRISTELIJK HOGER ONDERWIJS ,  WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG

Inventor： ROLF JONAS NILSSON ,  THOMAS WÜRDINGER

IPC: G01N33/48

Abstract: método de análise de uma amostra de sangue de um indivíduo para a presença de um marcador de doença. a presente invenção refere-se a um método de análise de uma amostra de sangue de um individuo para a presença de um marcador de doença, o referido método compreendendo as etapas de a) extração nucleicos de células de sangue anucleadas na referida amostra de sangue para fornecer uma fração de ácidos nucléicos extraídos de células de sangue anucleadas, e b) análise da referida fração de ácidos nucléicos extraídos de células de sangue anucleadas para a presença de um marcador de doença, em que o referido marcador de doença é uma mutação específica da doença em um gene de uma célula do referido indivíduo, ou em que o referido marcador de doença é perfil de expressão de doenças específicas de genes de uma célula do referido indivíduo.

公开(公告)号：AU2019270624A1

公开(公告)日：2020-11-26

申请号：AU2019270624

申请日：2019-05-15

Applicant: JANSSEN BIOTECH INC ,  STICHTING VUMC

Inventor： ADAMS HOMER ,  GAUDET FRANCOIS ,  FRERICHS KRIS ,  VAN DE DONK NIELS ,  VERLEIJ CHRISTIE C P M

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  C07K16/30 ,  C07K16/46 ,  C07K19/00

Abstract: The disclosure provides methods of treating a cancer and/or killing tumor cells in a subject, comprising administering a therapeutically effective amount of an anti-CD38 antibody and a T cell redirecting therapeutic to the subject to treat the cancer. The disclosure provides a method of enhancing efficacy of a T cell redirecting therapeutic in a subject having a cancer, comprising administering to the subject an anti-CD38 antibody. The disclosure also provides a method of treating a multiple myeloma in a subject, comprising administering a therapeutically effective amount of a BCMAxCDS bispecific antibody and an anti-CD38 antibody to the subject to treat the multiple myeloma. The disclosure also provides a pharmaceutical combination comprising a GPRC5DxCD3 bispecific antibody. The disclosure also provides a kit comprising a pharmaceutical composition comprising a BCMAxCD3 bispecific antibody and an anti-CD38 antibody.

公开(公告)号：NL2022494B1

公开(公告)日：2020-08-19

申请号：NL2022494

申请日：2019-02-01

Applicant: LAVA THERAPEUTICS B V ,  STICHTING VUMC

Inventor： JOHANNES JELLE VAN DER VLIET ,  IRIS DE WEERDT ,  TANJA DENISE DE GRUIJL ,  PAUL PARREN ,  ARNON PHILIP KATER ,  GEORGE LODEWIJK SCHEFFER

IPC: A61P35/00 ,  C07K16/28

Abstract: The present invention relates to novel antibodies capable of binding human CD40 and to novel multispecific antibodies capable of binding human CD40 and capable of binding a human Vy9V82 T cell receptor. The invention further relates to 5 pharmaceutical compositions comprising the antibodies of the invention and to uses of the antibodies of the invention for medical treatment.

公开(公告)号：CA3064702A1

公开(公告)日：2018-11-29

申请号：CA3064702

申请日：2018-05-23

Applicant: STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKEUIS ,  STICHTING VUMC

Inventor： BOSCH LINDA JANNA WILLEMIEN ,  DE WIT MEIKE ,  PINTO MORAIS DE CARVALHO BEATRIZ ,  FIJNEMAN REMONDUS JOHANNES ADRIAAN ,  JIMENEZ CORNELIA RAMONA ,  MEIJER GERRIT ALBERT ,  COUPE VEERLE MARLEEN HERMAN

IPC: G01N33/574

Abstract: The invention relates to methods for typing a sample of an individual suffering from a colorectal cancer, or suspected of suffering therefrom. A preferred sample is stool. The invention further relates to methods for determining a level of expression of at least two extracted protein expression molecules in stool,, based on the quantified reaction products, and to methods of assigning treatment to an individual that was typed as suffering from colorectal cancer according to the invention.

公开(公告)号：DK2717883T3

公开(公告)日：2017-04-24

申请号：DK11731142

申请日：2011-05-02

Applicant: STICHTING VUMC

Inventor： VAN NIEUW AMERONGEN GEERTEN P ,  VONK NOORDEGRAAF ANTON ,  AMAN JURJAN ,  VAN HINSBERGH VICTOR W M

IPC: C12N15/113 ,  A61K31/506 ,  A61K31/713 ,  C07K16/18

公开(公告)号：SG11201609417VA

公开(公告)日：2016-12-29

申请号：SG11201609417V

申请日：2015-04-10

Applicant: STICHTING VUMC

Inventor： VAN DER VLIET JOHANNES JELLE ,  DE BRUIN RENÉE CORNELIA GERARDA ,  DE GRUIJL TANJA DENISE ,  VERHEUL HENDRIK MARINUS WILLEM

IPC: C07K16/28

Abstract: The invention is in the field of medicine and relates to immunology, and relates in particular to human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules. Human Vγ9Vδ2 T cell receptor binding immunoglobulin molecules are in particular for use in medical treatment and/or useful in assays with human Vγ9Vδ2 T cells, wherein human Vγ9Vδ2 T cells may be modulated.

公开(公告)号：AU2022245215A9

公开(公告)日：2023-10-19

申请号：AU2022245215

申请日：2022-03-22

Applicant: MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES ,  MEMORIAL SLOAN KETTERING CANCER CENTER ,  SLOAN KETTERING INST CANCER RES ,  STICHTING VUMC

Inventor： SADELAIN MICHEL ,  THEMELI MARIA ,  SJÖSTRAND MARIA ,  KATSAROU AFRODITI

IPC: C07K16/30 ,  A61K35/17 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  C07K16/40

Abstract: The presently disclosed subject matter provides uses of a chimeric costimulatory receptor (CCR) targeting CD38, and cells comprising a CD38 CCR and an antigen-recognizing receptor, and uses of such cells.

公开(公告)号：CA3213040A1

公开(公告)日：2022-09-29

申请号：CA3213040

申请日：2022-03-22

Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER ,  MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES ,  STICHTING VUMC ,  SLOAN KETTERING INST CANCER RES

Inventor： SADELAIN MICHEL ,  THEMELI MARIA ,  SJOSTRAND MARIA ,  KATSAROU AFRODITI

IPC: C07K16/30 ,  A61K35/17 ,  A61P35/02 ,  A61P37/02

Abstract: The presently disclosed subject matter provides uses of a chimeric costimulatory receptor (CCR) targeting CD38, and cells comprising a CD38 CCR and an antigen-recognizing receptor, and uses of such cells.

公开(公告)号：NL2027228B1

公开(公告)日：2022-07-20

申请号：NL2027228

申请日：2020-12-24

Applicant: STICHTING VUMC

Inventor： RENSKE DANIËLA MARIA STEENBERGEN ,  SANDER BACH ,  GEERT KAZEMIER

IPC: C12Q1/6886

Abstract: The invention relates to means and methods for detecting or determining the level of nucleic acid in urine of a human subject, the method comprising the steps of collecting nucleic acid from a sample of at least 10 ml, preferably at least 20 ml of urine of said subject, processing the sample to isolate cell free nucleic acid enriched for fragments of 150 nucleic acid bases or less, and determining whether the enriched nucleic acid comprises methylated nucleic acid of the SEPTlN-9 gene or a promoter region thereof and methylated nucleic acid of the SDC2 gene or a promoter region thereof. The means and methods may be used to arrive at a diagnosis of colorectal cancer, colorectal metastasis, recurrent colorectal cancer or a combination thereof in the human subject. The invention further relates to methods of treatment of human subjects with colorectal cancer, colorectal metastasis, recurrent colorectal cancer or a combination thereof comprising using the means and methods.

公开(公告)号：GB202109941D0

公开(公告)日：2021-08-25

申请号：GB202109941

申请日：2021-07-09

Applicant: CAMBRIDGE ENTPR LTD ,  STICHTING VUMC